Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Investing in an eyelash serum, of course. Not everyone is blessed with luscious lashes that would put their local lash tech out of business, or can afford a lash lift and tint every month, so aside ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Beauty insiders share the philosophies that guide them, the routines they swear by, and the trends set to define the future of skincare.

It’s all too easy to believe the hype of certain wonder supplements, including collagen, but all is not necessarily as it ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Researchers discovered peptides that permanently block a key cancer protein once thought untreatable, using a new screening ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Perhaps the most talked-about collagen brand on the market is Vital Proteins. Haven’t tried it yet? Now’s the time to do so, ...